Back to Trials
NCT07082829PHASE1RecruitingAccepts Healthy Volunteers

A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age

Centessa Pharmaceuticals (UK) Limited

Start Date

6/30/2025

Completion Date

6/15/2026

Summary

Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.

Eligibility Criteria

Age Range: 18 years to 80 years

Key Inclusion Criteria: 1. Healthy males or females as determined by assessments at the Screening Visit. For Parts A, B, C, and E: a. Participants must be at least 18 years of age and no more than 55 years of age at the Screening 2. For Part D: a .Participants must be at least 60 years of age and no more than 80 years of age at the Screening Key Exclusion Criteria: 1. Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations. 2. History of seizure disorder, any other condition that increases the risk of seizure 3. Has a clinically significant sleep disorder, including insomnia or sleep apnea.

Interventions

DRUG

ORX142 Tablets

OTHER

Placebo Tablets

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Excessive Daytime Sleepiness

Locations

Site #1

Lincoln, Nebraska 68502

United States

Site #2

Eatontown, New Jersey 07724

United States

Site #3

New York, New York 10019

United States